Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC): A prospective phase II study

被引：0
|
作者：
Gui, L. [1 ]
Chen, X. [2 ]
He, X. [1 ]
Yang, J. [3 ]
Liu, P. [1 ]
Qin, Y. [1 ]
Shi, Y-K. [4 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticancer Mol Targete, Natl Clin Res Ctr Canc, Canc Hosp,Natl Canc Ctr,Dept Med Oncol, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, CAMS PUMC, Dept Med Oncol, Beijing, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.468
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
360MO
引用
收藏
页码：S1609 / S1610
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study
    Shi, Y-K.
    Gao, L.
    Tian, Y.
    Chen, J.
    Wang, J.
    Bai, C.
    Li, X.
    Su, H.
    Liu, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S806 - S806
  • [32] Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC)
    Bauman, Julie E.
    Arias-Pulido, Hugo
    Lee, Sang-Joon
    Considine, Michael
    Fekrazad, M. Houman
    Howard, Jason
    Bishop, Justin A.
    Olson, Garth T.
    Jones, Dennie V.
    Fertig, Elana J.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Chow, Laura Quan Man
    Mehra, Ranee
    Haddad, Robert I.
    Mahipal, Amit
    Weiss, Jared
    Berger, Raanan
    Eder, Joseph Paul
    Burtness, Barbara
    Tahara, Makoto
    Keam, Bhumsuk
    Le, Dung T.
    Muro, Kei
    Geva, Ravit
    Chung, Hyun Cheol
    Lin, Chia-Chi
    Ayers, Mark
    Aurora-Garg, Deepti
    Lunceford, Jared K.
    Cheng, Jonathan D.
    Seiwert, Tanguy Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Final Analysis of the Phase 4 KEYNOTE-B10 Study: First-Line(1L) Pembrolizumab (pembro) plus Carboplatin (carbo) plus Paclitaxel (pacli) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
    Dzienis, M.
    Cundom, J.
    Fuentes, C. S.
    Spreafico, A.
    Nordlinger, M. J.
    Pastor, A. V.
    Alesi, E.
    Neki, A.
    Fung, A. S.
    Lima, I. P. Figueiredo
    Oppelt, P.
    da Cunha Junior, G. F.
    Franke, F. A.
    Tseng, J.
    Joshi, A. J.
    McCarthy, J.
    Sidi, Y.
    Gumuscu, B.
    Naicker, N.
    de Castro, G., Jr.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E3 - E4
  • [35] Weekly paclitaxel, carboplatin and cetuximab (PCC) as first-line treatment of recurrent and/or metastatic head & neck squamous cell carcinoma (R/M-HNSCC) for patients ineligible to cisplatin based chemotherapy
    Carinato, H.
    Burgy, M.
    Fischbach, C.
    Kalish-Weindling, M.
    Pabst, L.
    Frasie, V.
    Thiery, A.
    Coliat, P.
    Demarchi, M. F.
    Petit, T.
    Borel, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S668 - S668
  • [36] Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
    Colevas, D. A.
    Misiukiewicz, K.
    Pearson, A. T.
    Fayette, J.
    Bauman, J. R.
    Cupissol, D.
    Saada-Bouzid, E.
    Adkins, D. R.
    Marie, D. B.
    Cornen, S. L.
    Andre, P.
    Carrette, F.
    Rotolo, F.
    Boyer Chammard, A.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1432 - S1432
  • [37] Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial
    Yoshino, Takayuki
    Hasegawa, Yasuhisa
    Takahashi, Shunji
    Monden, Nobuya
    Homma, Akihiro
    Okami, Kenji
    Onozawa, Yusuke
    Fujii, Masato
    Taguchi, Takahide
    de Blas, Barbara
    Beier, Frank
    Tahara, Makoto
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (05) : 524 - 531
  • [38] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA IN COLOMBIA
    Urrego-Reyes, J.
    Lopez, C.
    Marrugo, A. C.
    Wurcel, V
    Khandelwal, A.
    Patel, A.
    Black, C.
    VALUE IN HEALTH, 2023, 26 (06) : S95 - S95
  • [39] Real-world use of first-line pembrolizumab plus platinum plus taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma
    Black, Christopher M.
    Zheng, Dandan
    Hair, Gleicy M.
    Ai, Lei
    Wang, Liya
    Goto, Daisuke
    Lerman, Nati
    Bidadi, Behzad
    Hanna, Glenn J.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [40] A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck
    Thomas, Jacob Stephen
    Bruce, Justine Yang
    Li, Zujun
    Lorch, Jochen H.
    Phillips, Tanyanika
    Villaflor, Victoria
    Ruel, Christopher
    Palmer, Joycelynne
    Gutkind, J. Silvio
    Villalona-Calero, Miguel Angel
    Colevas, Alexander Dimitrios
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345